Cefepime Dosing for Hospital-Acquired Pneumonia
For moderate to severe hospital-acquired pneumonia, administer cefepime 2 g IV every 8 hours for 10 days, with mandatory dose adjustments based on creatinine clearance. 1
Standard Dosing Algorithm
For Normal Renal Function (CrCl >60 mL/min)
- Dose: 2 g IV every 8 hours
- Infusion time: 30 minutes (standard) or consider 3-hour extended infusion for enhanced pharmacodynamic target attainment
- Duration: 10 days 1
The 2016 IDSA/ATS guidelines specifically recommend cefepime 2 g IV every 8 hours as a primary antipseudomonal β-lactam option for empiric treatment of hospital-acquired pneumonia, particularly when Pseudomonas aeruginosa coverage is needed 2. This dosing achieves optimal pharmacodynamic exposure against common HAP pathogens.
Renal Function-Based Dose Adjustments
You must adjust dosing when CrCl ≤60 mL/min 1:
| CrCl (mL/min) | Adjusted Dose |
|---|---|
| 30-60 | 2 g every 12 hours |
| 11-29 | 2 g every 24 hours |
| <11 | 1 g every 24 hours |
| Hemodialysis | 1 g on day 1, then 1 g every 24 hours (give after dialysis on dialysis days) |
| CAPD | 2 g every 48 hours |
Critical Considerations for Optimization
Extended Infusions
The guidelines note that extended infusions may be appropriate for pharmacokinetic/pharmacodynamic optimization 2. Research demonstrates that 3-hour infusions of cefepime 2 g every 8 hours achieve superior target attainment rates compared to standard 30-minute infusions, particularly for organisms with MICs of 8-16 mcg/mL 3, 4. Monte Carlo simulations show that prolonged infusions increase the probability of maintaining free drug concentrations above the MIC for 50% of the dosing interval from 78.1% to 95.3% at MIC 16 mcg/mL 4.
Special Populations
Critically ill patients on ECMO: Recent 2025 data reveals that ECMO increases cefepime volume of distribution 2.8-fold without altering clearance 5. A 3 g loading dose is essential in ECMO patients to achieve adequate target attainment, followed by standard maintenance dosing adjusted for renal function 5.
Patients with augmented renal clearance: Standard dosing may be inadequate. Consider therapeutic drug monitoring if available, as critically ill patients often require higher or more frequent dosing to maintain adequate concentrations 3, 6.
Common Pitfalls to Avoid
Failing to adjust for renal impairment: Cefepime accumulation in renal dysfunction significantly increases neurotoxicity risk, including seizures. Always calculate CrCl using the Cockcroft-Gault equation and adjust accordingly 1.
Using inadequate dosing for Pseudomonas: The FDA label explicitly states "For Pseudomonas aeruginosa, use 2 g IV every 8 hours" 1. Do not use lower doses or extended intervals for suspected or confirmed pseudomonal pneumonia.
Overlooking combination therapy requirements: Cefepime monotherapy is insufficient for empiric HAP/VAP treatment. The IDSA/ATS guidelines mandate combining cefepime with either a fluoroquinolone or aminoglycoside for double gram-negative coverage in high-risk settings 2.
Ignoring local antibiogram data: Empiric regimen selection must incorporate institutional resistance patterns. If local Pseudomonas resistance to cefepime exceeds 10%, alternative or dual antipseudomonal coverage is required 2.
Practical Implementation
Calculate creatinine clearance using: CrCl (mL/min) = [Weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)] (multiply by 0.85 for females) 1.
Administer doses at consistent times daily, particularly in dialysis patients where timing relative to dialysis sessions affects drug clearance 1. The pharmacokinetic model demonstrates that cefepime clearance directly correlates with renal function (K₁₀ = 0.0027 × CrCl + 0.071 h⁻¹), making precise renal assessment critical 3.
Population pharmacokinetic approaches demonstrate improved clinical cure rates (50% vs 36.5%) compared to traditional empiric dosing in HAP/VAP patients, supporting individualized dosing strategies when feasible 6.